Literature DB >> 14560221

Tissue (muscle) oxygen saturation (StO2): a new measure of symptomatic lower-extremity arterial disease.

Anthony J Comerota1, Richard C Throm, Patrick Kelly, Michael Jaff.   

Abstract

OBJECTIVES: Near-infrared spectroscopy provides a noninvasive method of measuring tissue oxygen saturation and has been used to monitor extremity compartment syndrome. Tissue O(2) saturation (StO(2)) is potentially useful in assessing patients with peripheral arterial disease (PAD). The purposes of this feasibility study are to (1) explore the diagnostic sensitivity of StO(2) in subjects with PAD and symptoms of intermittent claudication (IC) compared with normal subjects, and (2) correlate the change in StO(2) during and after exercise with the ankle brachial index (ABI) in patients with IC. Material and methods Forty-nine subjects, 35 normal and 14 PAD, from two centers were evaluated in a prospective cross-sectional analysis comparing StO(2) by using the InSpectra tissue spectrometer and ABI at rest (baseline) and after treadmill exercise. Measurements were obtained at baseline and peak exercise (normal subjects) and at baseline, initial claudication distance (ICD) and absolute claudication distance (ACD) in PAD subjects. Endpoint values were the mean of 15 data points. Times to 50% of StO(2) recovery to baseline (T(50)) and complete recovery to baseline (T(100)) were measured. Receiver-operator characteristic curves were constructed to assess the sensitivity/specificity values associated with various StO(2) cut-points.
RESULTS: The PAD patients were older (P =.0002) and 57% were male, compared with 37% males in the normal group. The ABI was 0.68 +/- 0.14 in PAD patients versus 1.14 +/- 0.08 in normal subjects (P <.0001). The baseline StO(2) was 65% in both groups. The peak exercise StO(2) was significantly lower and the absolute change in StO(2) and the percent change in StO(2) were significantly greater in PAD patients (P < 0.45). The T(50) and T(100) were longer in the PAD patients compared to normal subjects (P =.0001 and.002, respectively). A T(50) of >70 seconds yielded a sensitivity of 89% and a specificity of 85% for PAD.
CONCLUSIONS: StO(2) is a new and potentially useful technique to evaluate patients with PAD. Resting StO(2) was similar in PAD-IC subjects and normals. There was a significantly greater drop in StO(2) and longer recovery times in PAD-IC subjects. Interestingly, StO(2) at the ICD and ACD was similar. StO(2) offers a different and perhaps more appropriate end point for diagnosis and monitoring of the management of patients with PAD, and may offer additional insight into the pathophysiology of exercise-induced muscle ischemia and its recovery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14560221     DOI: 10.1016/s0741-5214(03)01032-2

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  26 in total

1.  Quantifying the effect of adipose tissue in muscle oximetry by near infrared spectroscopy.

Authors:  Nassim Nasseri; Stefan Kleiser; Daniel Ostojic; Tanja Karen; Martin Wolf
Journal:  Biomed Opt Express       Date:  2016-10-17       Impact factor: 3.732

2.  Reduced high-density lipoprotein level is linked to worse ankle brachial index and peak oxygen uptake in postmenopausal women with peripheral arterial disease.

Authors:  Karin Mauer; J Emilio Exaire; Julie A Stoner; Leslie D Guthery; Polly S Montgomery; Andrew W Gardner
Journal:  Angiology       Date:  2010-06-07       Impact factor: 3.619

3.  A low-cost, wireless near-infrared spectroscopy device detects the presence of lower extremity atherosclerosis as measured by computed tomographic angiography and characterizes walking impairment in peripheral artery disease.

Authors:  Matthew A Fuglestad; Hernan Hernandez; Yue Gao; Henamari Ybay; Molly N Schieber; Katyarina E Brunette; Sara A Myers; George P Casale; Iraklis I Pipinos
Journal:  J Vasc Surg       Date:  2019-08-21       Impact factor: 4.268

4.  Clinical significance of ankle systolic blood pressure following exercise in assessing calf muscle tissue ischemia in peripheral artery disease.

Authors:  Aman Khurana; Julie A Stoner; Thomas L Whitsett; Suman Rathbun; Polly S Montgomery; Andrew W Gardner
Journal:  Angiology       Date:  2012-05-17       Impact factor: 3.619

Review 5.  Cutaneous Imaging Technologies in Acute Burn and Chronic Wound Care.

Authors:  Chandan K Sen; Subhadip Ghatak; Surya C Gnyawali; Sashwati Roy; Gayle M Gordillo
Journal:  Plast Reconstr Surg       Date:  2016-09       Impact factor: 4.730

6.  Evaluation of cuff-induced ischemia in the lower extremity by magnetic resonance oximetry.

Authors:  Michael C Langham; Thomas F Floyd; Emile R Mohler; Jeremy F Magland; Felix W Wehrli
Journal:  J Am Coll Cardiol       Date:  2010-02-09       Impact factor: 24.094

7.  Low tissue oxygen saturation is associated with requirements for transfusion in the rural trauma population.

Authors:  Mohammad A Khasawneh; Martin D Zielinski; Donald H Jenkins; Scott P Zietlow; Henry J Schiller; Mariela Rivera
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

8.  Calf muscle hemoglobin oxygen saturation characteristics and exercise performance in patients with intermittent claudication.

Authors:  Andrew W Gardner; Donald E Parker; Nykita Webb; Polly S Montgomery; Kristy J Scott; Steve M Blevins
Journal:  J Vasc Surg       Date:  2008-06-24       Impact factor: 4.268

9.  Sex differences in calf muscle hemoglobin oxygen saturation in patients with intermittent claudication.

Authors:  Andrew W Gardner; Donald E Parker; Polly S Montgomery; Steve M Blevins; Raha Nael; Azhar Afaq
Journal:  J Vasc Surg       Date:  2009-02-15       Impact factor: 4.268

10.  Effects of exercise training on calf muscle oxygen extraction and blood flow in patients with peripheral artery disease.

Authors:  Wesley B Baker; Zhe Li; Steven S Schenkel; Malavika Chandra; David R Busch; Erin K Englund; Kathryn H Schmitz; Arjun G Yodh; Thomas F Floyd; Emile R Mohler
Journal:  J Appl Physiol (1985)       Date:  2017-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.